Results 141 to 150 of about 53,515 (238)

European Consortium for Lipodystrophies consensus definition and classification framework for monogenic lipodystrophy

open access: yesJournal of Internal Medicine, Volume 300, Issue 6, Page 725-742, December 2026.
Abstract Lipodystrophy comprises a heterogeneous group of disorders characterized by reduced adipose tissue often associated with severe metabolic complications. Lipodystrophy may be genetic, acquired, or secondary to medical therapies initiated for other conditions.
Robert K. Semple   +25 more
wiley   +1 more source

Case Report Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma

open access: yes, 2020
Objective. Thyroid disease has been reported among the endocrinopathies that can occur after treatment with ipilimumab. Graves' disease, however, has been rarely reported with this medication.
Amy Joehlin-Price   +4 more
core  

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3972-3981, November 2026.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller   +9 more
wiley   +1 more source

Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Neoadjuvant therapy has become an integral component of the multidisciplinary management of resectable non–small cell lung cancer (NSCLC). The introduction of immune checkpoint inhibitors (ICIs) has transformed the perioperative treatment landscape by improving pathological response rates, reducing the risk of recurrence, and offering the ...
Hao An   +15 more
wiley   +1 more source

Investigating Risk Factors for Delayed Melanoma Recurrence Beyond 5 Years Post‐Primary Tumor Diagnosis

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Patients undergoing treatment for cutaneous melanoma are generally considered cured after a period of 5 years, since most recurrences manifest within three to 5 years. However, some patients can present with a delayed recurrence of melanoma beyond a 10‐year timeframe.
Kaspar Itin   +18 more
wiley   +1 more source

Immune Checkpoint Inhibitor Rechallenge After Immune‐Related Adverse Events: A Systematic Review and Meta‐Analysis

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Restarting immune checkpoint inhibitors (ICIs) after an immune‐related adverse event (irAE) requires balancing toxicity against antitumor benefit. Prior reviews often mixed post‐irAE restart with retreatment after progression or combined cohorts with case reports. This systematic review evaluated cohort evidence on ICI restart after
Xinwei Chen   +6 more
wiley   +1 more source

Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real‐World Implementation and Clinical Outcomes

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Biliary Tract Cancers (BTCs) are difficult‐to‐treat malignancies with limited therapeutic options and dismal prognosis. Upfront comprehensive genomic profiling (CGP) is recommended for advanced BTC to identify actionable alterations, but its real‐world implementation remains underexplored. Methods In 2019, we implemented upfront CGP
Saskia Hussung   +13 more
wiley   +1 more source

Adjuvant Immunotherapy for Resected Head and Neck Mucosal Melanoma: A Retrospective Cohort Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Head and neck mucosal melanoma (HNMM) is a rare, aggressive malignancy with high recurrence rates and limited prospective data to guide postoperative management. While immune checkpoint inhibitors (ICI) have reshaped melanoma treatment, their survival impact in resected HNMM remains poorly defined.
Dary Phen   +9 more
wiley   +1 more source

Longitudinal Albumin–Bilirubin Trajectory and Survival During Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background and Aims The albumin–bilirubin (ALBI) score measures hepatic reserve in hepatocellular carcinoma (HCC). We evaluated the association between longitudinal ALBI changes during immune checkpoint inhibitor (ICI) therapy and overall survival (OS), including their prognostic contribution beyond baseline ALBI.
Alireza Tojjari   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy